Recent Updates
Recently added Catalysts
CELC Positive Sentiment

Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium

Wednesday, November 26, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Celcuity Inc. has announced that an abstract was accepted for an oral presentation at the 2025 San Antonio Breast Cancer Symposium. The presentation will feature updated efficacy and safety data from the PIK3CA Wild-Type cohort of the phase 3 VIKTORIA-1 trial. The event will take place from December 9-12, 2025, and highlights Celcuity's efforts in developing targeted therapies for advanced breast cancer.
Price reaction · baseline $99.08 (2025-11-25 close) · hit after-hours · 1 other CELC headline(s) in the window, move may be shared
day 0 close · peak
+1.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Celcuity's presentation at a significant oncology event indicates growing recognition in the field.
  • The updated data from the VIKTORIA-1 trial may provide new insights into treatment options for patients.
  • Acceptance of the abstract for an oral presentation demonstrates credibility and interest in Celcuity's research.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+27%
120-day peak, hindsight
Typical move
14.9%
average across 6 past catalysts
Cash runway
~41 mo
Minimal dilution risk
Lead asset
Gedatolisib
Phase 3 · Breast Cancer

Full Press Release Details

MINNEAPOLIS, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that an abstract was accepted for an oral presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS) and is now available on the SABCS website. The 2025 SABCS is being held virtually and in-person from December 9-12, 2025. The presentation will include additional sub-group efficacy analyses and safety data.
Abstract presentation details are provided below.
Abstract Title: Gedatolisib, a multi-target PI3K/AKT/mTOR (PAM) inhibitor, plus fulvestrant with or without palbociclib for second-line (2L) treatment of patients with HR+/HER2-/PIK3CA-wild type (WT) advanced breast cancer (ABC): updated results from the randomized, phase 3 VIKTORIA-1 trial
Author: Barbara Pistilli, MD
Presentation number: RF7-04
Session Title: Rapid Fire 7
Presentation Date: December 11, 2025
For more details about SABCS please visit: https://www.sabcs.org/.
View source version of release on GlobeNewswire.com

Frequently Asked Questions

What is the focus of Celcuity Inc.?

Celcuity Inc. develops targeted therapies for oncology.

When is the 2025 SABCS taking place?

The 2025 SABCS is from December 9-12, 2025.

Who authored the accepted abstract for SABCS?

The abstract was authored by Barbara Pistilli, MD.

What is the title of the abstract presented at SABCS?

The title is 'Gedatolisib, a multi-target PI3K/AKT/mTOR inhibitor...'.

What type of results will the presentation include?

It will include efficacy analyses and safety data.

ShareAdd on Google
Tags: CELC Viatris Investor Conferences Healthcare Celcuity VIKTORIA-1 breast cancer SABCS oncology
Last updated: Nov 26, 2025

Biotech snapshot

Cash runway
$754M liquidity · $18M/mo burn
~41 mo
Minimal dilution risk
Lead asset
GedatolisibPhase 3
Breast Cancer →

Catalyst track record

+27%
best trade around CELC's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for CELC.

See every catalyst's timing & PoA →